Crick
HomeTrialsGenesDrugs23andMeGraphBlogContact
  • Home
  • Trials
  • Genes
  • Drugs
  • 23andMe
  • Graph
  • Blog
  • Contact
Crick

An open-source clinical intelligence platform. Explore clinical trials, gene networks, and molecular structures using public data sources.

Data Sources

  • ClinicalTrials.gov
  • OpenTargets
  • ClinVar
  • PubChem

Links

  • Contact
  • Privacy

© 2026 Crick. All rights reserved.

Crick is for educational purposes only. Not medical advice.

Results for “KRAS p.G12C Mutant Advanced Solid Tumors”

24 trials

Filters

Phase
Early Phase 1
Phase 1
Phase 2
Phase 3
Phase 4
Status
Recruiting
Active, Not Recruiting
Not Yet Recruiting
Completed
Enrolling by Invitation

Showing 20 of 24 results

Testing effectiveness (Phase 2)Active Not RecruitingNCT05638295
What this trial is testing

Testing the Use of AMG 510 (Sotorasib) and Panitumumab as a Targeted Treatment for KRAS G12C Mutant Solid Tumor Cancers (A ComboMATCH Treatment Trial)

Who this might be right for
Advanced Malignant Solid NeoplasmMetastatic Malignant Solid Neoplasm
National Cancer Institute (NCI) 105
Early research (Phase 1)Active Not RecruitingNCT05631899
What this trial is testing

CAR-DC Vaccine and ICIs in Local Advanced/Metastatic Solid Tumors

Who this might be right for
Solid Tumor, AdultEphA2 OverexpressionKRAS G12V+2 more
Chinese PLA General Hospital 9
Early research (Phase 1)Looking for participantsNCT05067283
What this trial is testing

Calderasib (MK-1084) in KRAS Mutant Advanced Solid Tumors (MK-1084-001)

Who this might be right for
Advanced Solid Tumors
Merck Sharp & Dohme LLC 830
Early research (Phase 1)Ended earlyNCT04892017
What this trial is testing

Study of Inlexisertib (DCC-3116) in Participants With RAS/MAPK Pathway Mutant Solid Tumors

Who this might be right for
Non-Small Cell Lung CancerAdvanced Solid TumorMetastatic Solid Tumor
Deciphera Pharmaceuticals, LLC 91
Testing effectiveness (Phase 2)Study completedNCT05002270
What this trial is testing

JAB-21822 Activity in Adult Patients With Advanced Solid Tumors Harboring KRAS G12C Mutation

Who this might be right for
Advanced Solid TumorNSCLCCRC
Jacobio Pharmaceuticals Co., Ltd. 29
Testing effectiveness (Phase 2)Active Not RecruitingNCT04699188
What this trial is testing

Study of JDQ443 in Patients With Advanced Solid Tumors Harboring the KRAS G12C Mutation

Who this might be right for
KRAS G12C Mutant Solid TumorsCarcinoma, Non-Small-Cell LungCarcinoma, Colorectal+7 more
Novartis Pharmaceuticals 344
Testing effectiveness (Phase 2)Ended earlyNCT06024174
What this trial is testing

BMS-986466 With Adagrasib With or Without Cetuximab in Participants With Kirsten Rat Sarcoma Virus Glycine 12 to Cysteine (KRAS G12C)-Mutant Solid Tumors

Who this might be right for
Advanced Solid Tumors
Bristol-Myers Squibb 5
Early research (Phase 1)Study completedNCT06235983
What this trial is testing

LY3537982 in Chinese Participants With Advanced Solid Tumors

Who this might be right for
Advanced Solid Tumors
Eli Lilly and Company 12
Testing effectiveness (Phase 2)Looking for participantsNCT07629960
What this trial is testing

A First-in-Human Trial of BLU-924 (SAR449336) in Advanced Solid Tumors Harboring KRAS Mutations

Who this might be right for
Advanced Solid TumorNon-Small Cell Lung CancerColorectal Neoplasms+1 more
Blueprint Medicines Corporation 265
Testing effectiveness (Phase 2)Looking for participantsNCT06959615
What this trial is testing

A Phase I/IIa Study of JAB-23E73 in Patients With Advanced Solid Tumors Harboring KRAS Gene Alteration

Who this might be right for
Advanced Solid Tumor
Jacobio Pharmaceuticals Co., Ltd. 334
Early research (Phase 1)Ended earlyNCT03114319
What this trial is testing

Dose Finding Study of TNO155 in Adult Patients With Advanced Solid Tumors

Who this might be right for
Advanced EGFR Mutant Non Small Cell LungCancer (NSCLC)KRAS G12-mutant NSCLCEsophageal Squamous Cell Cancer (SCC)+4 more
Novartis Pharmaceuticals 227
Testing effectiveness (Phase 2)Active Not RecruitingNCT04956640
What this trial is testing

Study of LY3537982 in Cancer Patients With a Specific Genetic Mutation (KRAS G12C)

Who this might be right for
Carcinoma, Non-Small-Cell LungColorectal NeoplasmsEndometrial Neoplasms+3 more
Eli Lilly and Company 540
Testing effectiveness (Phase 2)Looking for participantsNCT07209111
What this trial is testing

A Clinical Study of Calderasib (MK-1084) in People With Advanced Solid Tumors (MK-1084-014)

Who this might be right for
Neoplasm Malignant
Merck Sharp & Dohme LLC 150
Testing effectiveness (Phase 2)Looking for participantsNCT06128551
What this trial is testing

Study of Elironrasib and Daraxonrasib as Monotherapies and Combination Therapy in Participants With Advanced KRAS G12C Mutant Solid Tumors

Who this might be right for
Non-Small Cell Lung Cancer (NSCLC)Colorectal CancerPancreatic Ductal Adenocarcinoma
Revolution Medicines, Inc. 534
Early research (Phase 1)Looking for participantsNCT06917079
What this trial is testing

BBO-11818 in Adult Subjects With KRAS Mutant Cancer

Who this might be right for
Non-Small Cell Lung CancerNSCLCPDAC - Pancreatic Ductal Adenocarcinoma+11 more
TheRas, Inc., d/b/a BBOT (BridgeBio Oncology Therapeutics) 665
Testing effectiveness (Phase 2)Active Not RecruitingNCT05009329
What this trial is testing

JAB-21822 in Adult Patients With Advanced Solid Tumors Harboring KRAS p.G12C Mutation in China

Who this might be right for
NSCLCSolid Tumor
Allist Pharmaceuticals, Inc. 315
Testing effectiveness (Phase 2)Looking for participantsNCT07581912
What this trial is testing

Neoadjuvant Treatment of Fulzerasib Plus Cetuximab N01 in KRAS G12C Mutated Locally Advanced Colorectal Cancer With or Without Resectable Metastases

Who this might be right for
Colorectal CancerKRAS G12C Mutant Advanced Solid TumorsFulzerasib+1 more
Zhejiang University 40
Early research (Phase 1)UnknownNCT06006793
What this trial is testing

SY-5933 in Patients With Advanced Solid Tumors Harboring the KRAS p.G12C Mutation

Who this might be right for
Advanced Solid Tumor
Shouyao Holdings (Beijing) Co. LTD 50
Testing effectiveness (Phase 2)Study completedNCT03600883
What this trial is testing

A Phase 1/2, Study Evaluating the Safety, Tolerability, PK, and Efficacy of Sotorasib (AMG 510) in Subjects With Solid Tumors With a Specific KRAS Mutation (CodeBreaK 100)

Who this might be right for
KRAS p.G12C Mutant Advanced Solid Tumors
Amgen 713
Testing effectiveness (Phase 2)Looking for participantsNCT06973564
What this trial is testing

JAB-23E73 in Adult Participants With Advanced Solid Tumors With KRAS Alteration

Who this might be right for
Advanced Solid Tumors
Jacobio Pharmaceuticals Co., Ltd. 294
Next Page